Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [21] Inefficacy of Triple Therapy and Comparison of Two Different Bismuth-containing Quadruple Regimens as a Firstline Treatment Option for Helicobacter pylori
    Kekilli, Murat
    Onal, Ibrahim K.
    Ocal, Serkan
    Dogan, Zeynal
    Tanoglu, Alpaslan
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2016, 22 (05) : 366 - 369
  • [22] Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication
    Lee, Jung Won
    Kim, Nayoung
    Nam, Ryoung Hee
    Lee, Sun Min
    Soo In, Choi
    Kim, Jung Mogg
    Lee, Dong Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (04) : 666 - 672
  • [23] Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori
    Nyssen, Olga P.
    McNicholl, Adrian G.
    Gisbert, Javier P.
    HELICOBACTER, 2019, 24 (02)
  • [24] Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection
    Liu, Airu
    Wang, Yuxin
    Song, Yingxiao
    Du, Yiqi
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2020, 26 (02) : 78 - 83
  • [25] Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial
    Cho, Jun-Hyung
    Jin, So Young
    Park, Suyeon
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (06) : 923 - 929
  • [26] High Efficacy of 14-Day Triple Therapy-Based, Bismuth-Containing Quadruple Therapy for Initial Helicobacter pylori Eradication
    Sun, Qinjuan
    Liang, Xiao
    Zheng, Qing
    Liu, Wenzhong
    Xiao, Shudong
    Gu, Weiqi
    Lu, Hong
    HELICOBACTER, 2010, 15 (03) : 233 - 238
  • [27] Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Kim, Jae Hyun
    Jung, Kyoungwon
    Kim, Hae Koo
    Dal Lee, Young
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (06) : 1059 - 1066
  • [28] Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy
    Sun, Yingchao
    Zhu, Mengjia
    Yue, Lei
    Hu, Weiling
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (23)
  • [29] Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains
    Fiorini, Giulia
    Saracino, Ilaria Maria
    Zullo, Angelo
    Gatta, Luigi
    Pavoni, Matteo
    Vaira, Dino
    HELICOBACTER, 2017, 22 (06)
  • [30] Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial
    Liang, Jing Wen
    Xiong, Si
    Jia, Ye Gui
    Xiao, Dan
    Tan, Shi Yun
    Cao, Ji Wang
    Sun, Jun
    Tian, Xia
    Li, Shu Yu
    Chen, Rui Hong
    Ruan, Gui Zhen
    Xiong, Jian Guang
    Wang, Xiao Ming
    Xu, San Ping
    Qi, Li Ping
    Liu, Yun Hua
    Zhao, Yu Chong
    Bai, Shu Ya
    Chen, Wei
    Cao, Meng Die
    Peng, Wang
    Li, Yan Ling
    Yang, Yi Lei
    Chen, Shi Ru
    Cui, Hao Chen
    Liu, Lu Yao
    Zhou, Yi
    Cheng, Bin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (11) : 2293 - 2298